InsiderTrades.com logo
Colin John Meyer net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Colin Meyer Biography and Net Worth

Insider of Reata Pharmaceuticals
Colin J. Meyer, M.D. joined Reata as one of our first employees in 2003, served as Chief Medical Officer until July 2020 and was appointed Chief Research and Development Officer in July 2020.

Dr. Meyer received a B.S. in chemistry with specialization in biochemistry and a B.A. in biology from the University of Virginia. He received an M.D. from the University of Texas Southwestern Medical School and an M.B.A. from Southern Methodist University Cox School of Business.

What is Colin John Meyer's net worth?

The estimated net worth of Colin John Meyer is at least $13.27 million as of June 14th, 2021. Dr. Meyer owns 77,000 shares of Reata Pharmaceuticals stock worth more than $13,271,720 as of April 3rd. This net worth evaluation does not reflect any other assets that Dr. Meyer may own. Additionally, Dr. Meyer receives an annual salary of $842,400.00 as Insider at Reata Pharmaceuticals. Learn More about Colin John Meyer's net worth.

How old is Colin John Meyer?

Dr. Meyer is currently 44 years old. There are 6 older executives and no younger executives at Reata Pharmaceuticals. The oldest executive at Reata Pharmaceuticals is Mr. Michael D. Wortley, Exec. VP and Chief Legal & Compliance Officer, who is 75 years old. Learn More on Colin John Meyer's age.

What is Colin John Meyer's salary?

As the Insider of Reata Pharmaceuticals, Inc., Dr. Meyer earns $842,400.00 per year. There are 2 executives that earn more than Dr. Meyer. The highest earning executive at Reata Pharmaceuticals is Mr. J. Warren Huff, Chairman, CEO & Sec., who commands a salary of $1,110,000.00 per year. Learn More on Colin John Meyer's salary.

How do I contact Colin John Meyer?

The corporate mailing address for Dr. Meyer and other Reata Pharmaceuticals executives is 5320 LEGACY DRIVE, PLANO TX, 75024. Reata Pharmaceuticals can also be reached via phone at (972) 865-2219 and via email at ir@reatapharma.com. Learn More on Colin John Meyer's contact information.

Has Colin John Meyer been buying or selling shares of Reata Pharmaceuticals?

Colin John Meyer has not been actively trading shares of Reata Pharmaceuticals within the last three months. Most recently, Colin John Meyer sold 20,000 shares of the business's stock in a transaction on Monday, June 14th. The shares were sold at an average price of $144.05, for a transaction totalling $2,881,000.00. Following the completion of the sale, the insider now directly owns 77,000 shares of the company's stock, valued at $11,091,850. Learn More on Colin John Meyer's trading history.

Who are Reata Pharmaceuticals' active insiders?

Reata Pharmaceuticals' insider roster includes Bhaskar Anand (CAO), Dawn Bir (Chief Commercial Officer), Elaine Castellanos (CAO), Samina Khan (SVP), Andrea Loewen (SVP), Colin Meyer (Insider), Shamim Ruff (Director), Manmeet Soni (CFO), and Michael Wortley (Insider). Learn More on Reata Pharmaceuticals' active insiders.

Colin John Meyer Insider Trading History at Reata Pharmaceuticals

See Full Table

Colin John Meyer Buying and Selling Activity at Reata Pharmaceuticals

This chart shows Colin John Meyer's buying and selling at Reata Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2$0Total Insider BuyingTotal Insider Selling

Reata Pharmaceuticals Company Overview

Reata Pharmaceuticals logo
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
Read More

Today's Range

Now: $172.36
Low: $172.32
High: $172.46

50 Day Range

MA: $171.30
Low: $168.70
High: $172.36

2 Week Range

Now: $172.36
Low: $21.83
High: $172.46

Volume

1,988,500 shs

Average Volume

1,091,032 shs

Market Capitalization

$6.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42